Trial Profile
Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibcasertib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Chipscreen Biosciences
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.